did fda ban bpc 157 Panel Recommends Compounding Unapproved Peptides Understanding the Legal Risks of

NHS B12 therapy is evidence-based for documented deficiency, using hydroxocobalamin 1mg intramuscularly with standardised protocols

It does not create a branded finished drug, it does not trigger insurance coverage, and it does not retroactively validate marketing claims made about the compound

For acute tendon or ligament injuries, typical anecdotal protocols suggest 250mcg to 500mcg twice daily, often administered near the site of injury for localized effect, though systemic routes are also used

Regulatory history: Sermorelin was FDA-approved in 1997 under the brand name Geref for the treatment of growth hormone deficiency in children